Promising cancer combo study pulled before it even started

This study aimed to see if adding two immune-boosting drugs (zimberelimab and domvanalimab) to standard chemotherapy could help people with operable stomach or esophageal cancer. All participants would have received the treatment before and after surgery, then be followed for up to 5 years. However, the study was withdrawn before enrolling any participants, so no results are available.